Sutro Biopharma Inc (STRO) — Titan Protect Analysis

STRO

Sutro Biopharma Inc

Healthcare · ·

$26.09

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$395M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-3.46

Based on estimated future earnings — lower means cheaper

Rev Growth

-16.5%

Year-over-year revenue change

Profit Margin

-154.2%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$50.00

+92% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 12 analysts covering this stock

About Sutro Biopharma Inc

Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer

https://www.sutrobio.com

Country: United States Employees: 133 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.371

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0173

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.171

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-15.3%

Historical annualised return based on price data

Max Drawdown

-89.6%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.64

Significantly more volatile than the market

52W High

$43.85

41% below the year high

52W Low

$6.70

289% above the year low

Avg Volume

263,958

Average daily shares traded — higher means easier to buy and sell

Short Ratio

5.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-16.35

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

-65.6%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-203.9%

Profit from core operations before interest and tax

Free Cash Flow

$-106,470,000

Negative — the business is spending more than it generates

Revenue (TTM)

$100M

Total revenue over the last 12 months

Net Income

$-153,602,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$61.00

Target Median

$50.00

Target Low

$10.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go